IP Library Granted Patent US 12,419,861
Granted Patent B2
US 12,419,861 · App. 17/707,784 · Granted Sep 23, 2025

Method for preventing and/or treating chronic traumatic encephalopathy-i

Inventor: Robert Vink (Mylor, AU)
Assignee: Eustralis Pharmaceuticals Limited (trading as PresSura Neuro)
A61K31/405A61K31/496A61P25/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,419,861
App. No.
17/707,784
Granted
Sep 23, 2025
Kind
B2
Abstract

The present invention relates to a method of preventing and/or treating chronic traumatic encephalopathy.

Claims (6)

1. A method of inhibiting tau hyperphosphorylation in a base of sulci in a subject who has suffered multiple concussive events, comprising administering to the subject a pharmaceutically acceptable composition consisting essentially of an NK1 receptor antagonist at a dose of from 0.25 mg/kg to 25 mg/kg effective to inhibit tau hyperphosphorylation in the subject, wherein the dose of NK1 receptor antagonist is effective to maintain NK1 receptor antagonist blood concentration in a therapeutic range for at least 3 days and inhibit tau hyperphosphorylation in the base of the sulci.

2. A method according to claim 1 , wherein the NK1 receptor antagonist is administered within 24 hours of the last concussive event.

3. A method according to claim 1 , wherein the NK1 receptor antagonist is one or more selected from Casopitant, CGP49823, CP-122,721, CP-96,345, CP-99,994, FK 888, GR 82334, GR 94800, GR203040, GR-205171, GSK1 144814, GSK206136, GSK424887, GW679769, HSP-117, L 703,606, L 732,138, L 733,060, L 742,694, L668,169, LY 303241, LY 303870, LY 306740, Maropitant, MEN 11149, Orvepitant, PD 154075, R-544, RP-67580, RPR 100893, SCH619734, Spantide II, Spantide III, Spendide, SR140333, Vestipitant, WIN-41,708, WIN-62,577, and pharmaceutically acceptable salts thereof.

4. A method according to claim 1 , wherein the NK1 receptor antagonist is Casopitant.

5. A method according to claim 1 , wherein the NK1 receptor antagonist is administered intravenously.

6. A method according to claim 1 , wherein the NK1 receptor antagonist is administered by direct injection.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2024
From: VINK, ROBERT
To: EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO)
Reel/Frame 069727/0895 →
Priority Claims (1)
AU 2013902455 · Jul 2, 2013 · national
Continuity (3)
Continuation 16945271 · Jul 31, 2020
Continuation 14902239
Related Publication 20220218663A1 · Jul 14, 2022
References Cited (34)
US 10729677B2 · Vink · 2020 [cited by applicant]
US 11426384B2 · Vink · 2022 [cited by examiner]
US 20060247240A1 · Hoffmann et al. · 2006 [cited by applicant]
US 20110053954A1 · Hoffmann et al. · 2011 [cited by applicant]
US 20110071135A1 · Chase et al. · 2011 [cited by applicant]
US 20140193526A1 · Henry · 2014 [cited by applicant]
US 20140323393A1 · Ruff · 2014 [cited by applicant]
US 20160013160A1 · Chun et al. · 2016 [cited by applicant]
US 20210100773A1 · Vink et al. · 2021 [cited by applicant]
CA 2831054A1 · 2013 [cited by applicant]
WO WO2008067610A1 · 2008 [cited by applicant]
WO WO2009009829A1 · 2009 [cited by applicant]
Kart-Teke et al., “Reinstatement of episodic-like memory in rats by neurokinin-1 receptor antagonism,” Neurobiol. Learn. Mem. Mar. 2007;87(3):324-31. PMID: 17079168. (Year: 2007). [cited by examiner]
Wang et al., “Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration,” J. Alzheimers Dis. 2013;33 Suppl 1:S123-39. PMID: 22710920. (Year: 2013). [cited by examiner]
Baugh et al., “Chronic traumatic encephalopathy: neurodegeneration following repetitive concussive and subconcussive brain trauma”, Brain Imaging and Behavior (2012) vol. 6, pp. 244-254. [cited by applicant]
Baylock et al., “Immunoexcitotoxicity as a central mechanism in chronic traumatic encephalopathy—A unifying hypothesis,” Surg Nerurol Int. (2011) 2: 107 (Published online Jul. 30, 2011). [cited by applicant]
Donkin et al., “Substance P is associated with the development brain edema and functional deficits after traumatic brain injury,” Journal of Cerebral Blood Flow & Metabolism, vol. 29, pp. 1388-1398 (2009) (Published onl… [cited by applicant]
Donkin et al., “A Substance P Antagonist Reduces Axonal Injury and Improves Neurologic Outcome When Administered U to 12 Hours after Traumatic Brain Injury,” Journal of Neurotrauma, vol. 28, pp. 217-224 (Feb. 2011). [cited by applicant]
Franz et al., “Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury”, Neurology (May 2013), vol. 60, No. 9, pp. 1457-1461. [cited by applicant]
Gao et al., “Chronic Traumatic Encephalopathy-like Neuropathological Findings without a History of Trauma,” International Journal of Pathology and Clinical Research, (Jan. 2017) vol. 3(1) pp. 1-4. [cited by applicant]
Gavett et al., “Mild traumatic brain injury: a risk factor for neurodegeneration,” Alzheimer's Research & Therapy, vol. 2, No. 18, pp. 1-3 (2010). [cited by applicant]
International Search Report issued on Sep. 8, 2014 in application No. PCT/AU2014/050107. [cited by applicant]
Johnson et al., “Acute and Chronically Increased Immunoreactivity to Phosphorylation-Independent but Not Pathological TDP-43 After a Single Traumatic Brain Injury in Humans,” Acta Neuropathol (Dec. 2011) vol. 122(6) pp.… [cited by applicant]
McKee et al., “Chronic Traumatic Encephalopathy in Athletes: Progressive Tauopathy After Repetitive Head Injury,” J. Neuropathol. Exp. Neurol., vol. 68, No. 7, pp. 709-735 (Jul. 2009). [cited by applicant]
McKee et al., “The Neuropathology of Chronic Traumatic Encephalopahty,” Brain Pathol. (May 2015) vol. 25, No. 3, pp. 350-364. [cited by applicant]
Neal et al., “Concussions: What a neurosurgeon should know about current scientific evidence and management strategies,” Surgical Neurology International, vol. 3, No. 16, pp. (Feb. 2015). [cited by applicant]
Office Action issued on Feb. 22, 2018 in U.S. Appl. No. 14/902,228 (US 2016-013160). [cited by applicant]
Office Action issued on Mar. 22, 2017 in U.S. Appl. No. 14/902,228 (US 2016-013160). [cited by applicant]
Office Action issued on Jul. 31, 2019 in U.S. Appl. No. 14/902,228 (US 2016-0136160). [cited by applicant]
Office Action dated Sep. 18, 2017 in U.S. Appl. No. 14/902,228 (US 2016-0136160). [cited by applicant]
Office Action issued on Apr. 8, 2020, in U.S. Appl. No. 14/902,228 (US 2016-0136160). [cited by applicant]
Saulle et al., “Chronic Traumatic Encephalopathy: A Review,” Rehabilitation Research and Practice (2012) vol. 2012 pp. 1-9. [cited by applicant]
Thornton et al., “Treatment with a Substance P Receptor Antagonist Is Neuroprotective in the Intrastriatal 6-Hydroxydopamine Model of Early Parkinson's Disease,” PLoS One, vol. 7, No., 4, e34138, pp. 1-8 (Apr. 2012). [cited by applicant]
Tran et al., “Inhibition of JNK by a Peptide Inhibitor Reduces Traumatic Brain Injury-Induced Tauopathy in Transgenic Mice,” J. Neuropathol Exp Neurol., (Feb. 2012) vol. 71, No. 2 pp. 116-129. [cited by applicant]